Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,673.00
Bid: 1,674.00
Ask: 1,675.00
Change: 3.00 (0.18%)
Spread: 1.00 (0.06%)
Open: 1,661.50
High: 1,679.50
Low: 1,658.50
Prev. Close: 1,670.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

12 Sep 2017 16:07

RNS Number : 5501Q
GlaxoSmithKline PLC
12 September 2017
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHELLFFDKFBBBE
Date   Source Headline
13th Jul 20219:33 amRNSDirector/PDMR Shareholding
12th Jul 202110:23 amRNSDirector/PDMR Shareholding
12th Jul 202110:18 amRNSDirector/PDMR Shareholding
9th Jul 20219:30 amRNSDirector/PDMR Shareholding
2nd Jul 202112:36 pmRNSGSK and Alector collaboration in immuno-neurology
2nd Jul 202110:41 amRNSElliott Advisors (UK) letter to GSK
1st Jul 20212:29 pmRNSTotal Voting Rights
25th Jun 20214:54 pmRNSDirector/PDMR Shareholding
24th Jun 202111:07 amRNSDirector/PDMR Shareholding
23rd Jun 202111:00 amRNSGSK to deliver step-change in growth & performance
22nd Jun 20217:00 amRNSViiV/Halozyme sign exclusive licensing agreement
14th Jun 202111:58 amRNSGSK and iTeos announce collaboration for EOS-448
11th Jun 20214:54 pmRNSDirector/PDMR Shareholding
9th Jun 20213:28 pmRNSDirector/PDMR Shareholding
4th Jun 20214:02 pmRNSGSK recommend ADR holders reject mini-tender offer
1st Jun 202111:33 amRNSTotal Voting Rights
27th May 20219:21 amRNSDirector/PDMR Shareholding
27th May 20217:00 amRNSSanofi and GSK initiate new Phase 3 clinical study
27th May 20217:00 amRNSGSK/Vir Sotrovimab FDA Emergency Use Authorization
24th May 202110:10 amRNSDirector/PDMR Shareholding
21st May 202112:58 pmRNSGSK/VIR sotrovimab receives positive EMA opinion
18th May 20211:52 pmRNSBlock listing Interim Review
18th May 20217:00 amRNSMedicago/GSK COVID-19 Vaccine Positive Ph2 Results
17th May 20217:00 amRNSSanofi/GSK COVID-19 Vaccine Positive Ph2 Results
13th May 20214:46 pmRNSDirector/PDMR Shareholding
11th May 202112:54 pmRNSDirector/PDMR Shareholding
11th May 202111:30 amRNSEMTN Prospectus
6th May 20215:50 pmRNSBoard and Committee Changes
5th May 20216:23 pmRNSResult of AGM
4th May 20214:29 pmRNSTotal Voting Rights
28th Apr 20215:33 pmRNSDirector/PDMR Shareholding
28th Apr 202112:00 pmRNS1st Quarter Results
26th Apr 20214:14 pmRNSDirector/PDMR Shareholding
23rd Apr 20213:00 pmRNSEU approves GSK’s JEMPERLI (dostarlimab-gxly)
23rd Apr 20217:00 amRNSFDA approves GSK’s JEMPERLI (dostarlimab-gxly)
16th Apr 20214:00 pmRNSDirector/PDMR Shareholding
15th Apr 20213:21 pmRNSDirector/PDMR Shareholding
15th Apr 202110:17 amRNSDirector/PDMR Shareholding
14th Apr 20212:14 pmRNSDirector/PDMR Shareholding
14th Apr 202111:58 amRNSDirector/PDMR Shareholding
12th Apr 20215:32 pmRNSDirector/PDMR Shareholding
12th Apr 20219:48 amRNSDirector/PDMR Shareholding
9th Apr 20215:34 pmRNSDirector/PDMR Shareholding
9th Apr 20211:35 pmRNSDirector/PDMR Shareholding
6th Apr 20212:30 pmRNSDirectorate Change
1st Apr 20213:36 pmRNSTotal Voting Rights
30th Mar 20214:21 pmRNSPublication of 2021 AGM Notice
30th Mar 202111:30 amRNSGSK respiratory product sales reporting changes
24th Mar 202112:30 pmRNSMoncef Slaoui Departs Galvani Bioelectronics
23rd Mar 20214:31 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.